InsuletPODD
PODD
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
150% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 5 (+3) [Q4]
133% more first-time investments, than exits
New positions opened: 121 | Existing positions closed: 52
13% more capital invested
Capital invested by funds: $16.3B [Q3] → $18.4B (+$2.06B) [Q4]
9% more funds holding
Funds holding: 610 [Q3] → 667 (+57) [Q4]
9% more repeat investments, than reductions
Existing positions increased: 242 | Existing positions reduced: 222
0.14% less ownership
Funds ownership: 100.59% [Q3] → 100.45% (-0.14%) [Q4]
31% less call options, than puts
Call options by funds: $123M | Put options by funds: $177M
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$293
11%
upside
Avg. target
$325
23%
upside
High target
$355
35%
upside
8 analyst ratings
7 positive
88%
1 neutral
13%
0 negative
0%
RBC Capital Shagun Singh 55% 1-year accuracy 37 / 67 met price target | 29%upside $340 | Outperform Initiated | 6 Mar 2025 |
Citigroup Joanne Wuensch 43% 1-year accuracy 22 / 51 met price target | 35%upside $355 | Buy Maintained | 21 Feb 2025 |
Raymond James Jayson Bedford 56% 1-year accuracy 14 / 25 met price target | 25%upside $328 | Outperform Reiterated | 21 Feb 2025 |
Stifel Mathew Blackman 24% 1-year accuracy 4 / 17 met price target | 11%upside $293 | Hold Maintained | 21 Feb 2025 |
Piper Sandler Matt O'Brien 40% 1-year accuracy 20 / 50 met price target | 18%upside $310 | Overweight Maintained | 21 Feb 2025 |
Financial journalist opinion
Based on 9 articles about PODD published over the past 30 days
Positive
Zacks Investment Research
1 week ago
Insulet Gains 62.9% in a Year: What's Driving the Stock?
PODD's shares rise on the back of its innovative Omnipod 5 system and impressive market expansion. However, the unfavorable macroeconomic scenario is concerning.
Positive
Zacks Investment Research
1 week ago
PODD Stock Gains Following the Launch of Omnipod 5 in Australia
Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.
Positive
Zacks Investment Research
1 week ago
PODD Stock to Gain From Favorable RADIANT Trial Results for Omnipod 5
Insulet unveils positive RADIANT trial clinical data for its Omnipod 5 at the 18th international conference on ATTD.
Neutral
Business Wire
1 week ago
Insulet's RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections
ACTON, Mass.--(BUSINESS WIRE)--Insulet's RADIANT trial demonstrates meaningful glycemic improvements with Omnipod 5 AID following direct transition from multiple daily injections.
Positive
Zacks Investment Research
1 week ago
3 Tariff-Proof Medical Device Stocks to Watch Amid Trump's MAGA Slogan
Tariffs are shaking up the Medical Device industry, but SYK, MDT & PODD are poised to thrive. Here's why three key players remain strong despite rising trade tensions.
Neutral
Business Wire
1 week ago
Insulet Announces Pricing of Senior Notes Due 2033
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has priced a private placement of $450 million aggregate principal amount of senior unsecured notes due 2033 (the “Notes”). The Notes will bear interest at an annual rate of 6.50% and will mature on April 1, 2033, unless earlier redeemed or repurchased. The closing of the private placement is expected to occur on March 20, 2025, subject to customary closing conditions.
Neutral
Business Wire
2 weeks ago
Insulet Announces Proposed Financing Transactions
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of senior unsecured notes due 2033 (the “Notes”) in a private placement. The Company intends to use the net proceeds from the Notes offering, together with cash on hand and potentially cash fr.
Positive
Seeking Alpha
2 weeks ago
Insulet Leans Bullish (Technical Analysis)
PODD exhibits bullish price action with a series of higher highs and lows, trading above its upward sloping 30-week EMA since August 2024. Momentum is long-term bullish but short-term bearish, with the PPO line above zero indicating positive long-term momentum. Volume analysis shows neutral to slightly bullish accumulation by institutional investors, with recent high volume supporting bullish price action.
Neutral
Business Wire
3 weeks ago
Insulet to Host Investor Day on June 5, 2025
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the Executive Leadership Team, and independent experts. The agenda will include a comprehensive overview of the Company's lea.
Positive
FXEmpire
1 month ago
Insulet Sales Keep Rising
Insulet Corporation (PODD) continues its strong sales and growth trend.
Charts implemented using Lightweight Charts™